Abstract
Background Differentiated service delivery (DSD) models aim to lessen the burden of HIV treatment on patients and providers in part by reducing requirements for facility visits and extending dispensing intervals. With the advent of the COVID-19 pandemic, minimizing patient contact with healthcare facilities and other patients, while maintaining treatment continuity and avoiding loss to care, has become more urgent, resulting in efforts to increase DSD uptake. We assessed the extent to which DSD coverage and antiretroviral treatment (ART) dispensing intervals have changed during the COVID-19 pandemic in Zambia.
Methods We used patient data from Zambia’s electronic medical record system (SmartCare) for 737 health facilities, representing about 3/4 of all ART patients nationally, to compare the numbers and proportional distributions of patients enrolled in DSD models in the six months before and six months after the first case of COVID-19 was diagnosed in Zambia in March 2020. Segmented linear regression was used to determine whether the introduction of COVID-19 into Zambia further accelerated the increase in DSD scale-up.
Results Between September 2019 and August 2020, 181,317 patients aged 15+ (81,520 and 99,797 from September 1, 2019 to March 1, 2020 and from March 1 to August 31, 2020, respectively) enrolled in DSD models in Zambia. Overall participation in all DSD models increased over the study period, but uptake varied by model. The rate of acceleration increased in the second period for home ART delivery (152%), ≤2-month fast-track (143%), and 3-month MMD (139%). There were significant decelerations in the increase in enrolment for 4-6-month fast-track (−28%) and ‘other’ models (−19%).
Conclusions Participation in DSD models for stable ART patients in Zambia increased after the advent of COVID-19, but dispensing intervals diminished. Eliminating obstacles to longer dispensing intervals, including those related to supply chain management, should be prioritized to achieve the expected benefits of DSD models and minimize COVID-19 risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for the study was provided by the Bill & Melinda Gates Foundation through OPP1192640 to Boston University. The funder had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study protocol was approved by ERES Converge IRB (Zambia), protocol number 2019-Sep-030, the Human Research Ethics Committee (Medical) of the University of Witwatersrand, protocol number M190453, and the Boston University IRB H-38823.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail addresses of authors:
YJ : youngji.jo{at}bmc.org
SR : sbrosen{at}bu.edu
KTLS : rsy{at}bu.edu
BP : bphiri{at}clintonhealthaccess.org
AH : ahuber{at}heroza.org
MM : muya.mwansa{at}gmail.com
HS : hshakwelele{at}clintonhealthaccess.org
PH : phaimbe{at}clintonhealthacces.org
MMM : mpande.mwenechanya{at}cidrz.org
PLM : priscillalloyd2{at}icloud.com
BEN: brooken{at}bu.edu
List of abbreviations
- ART
- Antiretroviral therapy
- CAG
- Community adherence group
- DSD
- Differentiated service delivery
- HIV
- Human immunodeficiency virus
- MMD
- Multi-month dispensing
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.